Advertisement

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials

  • Evandro de AzambujaEmail author
  • Noam Ponde
  • Marion Procter
  • Priya Rastogi
  • Reena S. Cecchini
  • Matteo Lambertini
  • Karla Ballman
  • Alvaro Moreno Aspitia
  • Dimitrios Zardavas
  • Lise Roca
  • Richard D. Gelber
  • Martine Piccart-Gebhart
  • Thomas Suter
Clinical trial

Abstract

Background

Trastuzumab-associated cardiotoxicity remains an issue for patients with HER2-positive breast cancer. This pooled analysis of 3 adjuvant trials investigated the incidence, timing, impact on treatment completion, and risk factors for trastuzumab-associated cardiotoxicity.

Methods

This is an individual patient data level pooled analysis of HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials). Definitions of cardiac events were as per each individual study.

Results

A total of 7445 patients enrolled in the 3 trials were included in the analysis, of which 4017 were in the trastuzumab and 3428 in the control (observation) arms, respectively. Median follow-up exceeded 10 years (119.2–137.2 months). Nearly all patients (97.4%) in the trastuzumab arms received anthracycline-based chemotherapy. In total, 452 patients in the trastuzumab arms experienced a cardiac event (11.3%), with most being mildly symptomatic or asymptomatic left ventricular ejection fraction (LVEF) decrease (351 patients, 8.7%). Severe congestive heart failure was more common in the trastuzumab arm (2.3%) than in the control arm (0.8%). Most cardiac events occurred during trastuzumab treatment (78.1%) and cardiac events were the main cause of discontinuation across the sample (10.0%); nevertheless, a large majority of patients completed trastuzumab treatment (76.2%). Baseline risk factors that were significantly associated with the development of cardiac events were baseline LVEF < 60%, hypertension, body mass index > 25, age ≥ 60 and, non-Caucasian ethnicity.

Conclusion

One year of trastuzumab increases the risk of cardiac events, though most consist of asymptomatic or mildly symptomatic LVEF drops. Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Trastuzumab-associated cardiotoxicity is the main cause of discontinuation and further research is needed to individualize prevention and management.

Keywords

Trastuzumab LVEF Cardiotoxicity Breast cancer 

Notes

Acknowledgements

The authors would like to acknowledge the teams of HERA, NSABP B-31, NCCTCG N9831, and PACS004 for their help in making this project possible.

Funding

The NSABP B-31 Trial was supported by NCI Grants: U10CA180868, -180822, UGICA-189867, and U24CA-196067.

Compliance with ethical standards

Conflict of interest

Evandro de Azambuja has received honoraria and advisory board from Roche/GNE and Seattle Genetics; travel grants from Roche/GNE and GSK/Novartis and research grants to his Institute: Roche/GNE; AstraZeneca, GSK/Novartis, Servier. Noam Pondé has received honoraria from AZ and Eli Lilly and travel grants from Eli Lilly and Novartis. Marion Procter has declared that her institution received funding from Roche in respect to the HERA and APHINITY trials. Matteo Lambertini has received honoraria from Theramex and consulting fee from TEVA. Pryia Rastogi has received travel and accommodations supported by Lilly, AZ, and GNE/Roche. Martine Piccart has been declared board Member (Scientific Board): Oncolytics, Radius; consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Periphagen, Pfizer, Roche, Seattle Genetics; research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Thomas Suter has declared research support from Novartis and Amgen; consultant from Pfizer and advisory Board from Alnylam. Richard D Gelber declares that his institution receives support for his salary from Roche, AstraZeneca, Merck, Novartis, Ipsen, Celgene, Pfizer, and Ferring. Dimitrios Zardavas has declared employment from BMS. Karla V. Ballman has declared consulting or Advisory Role from ARIAD; Medtronic; Takeda; Agenus; Patents, Royalties, Other Intellectual Property: Prostate cancer signature patent (Inst); Expert Testimony—Janssen Oncology; Lilly. Lise Roca, Alvaro Moreno Aspitia, and Reena Cecchini have no conflict of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in each of the studies (HERA, NSABP B-31 (NRG Oncology) and NCCTG N9831 (Alliance)).

Supplementary material

10549_2019_5453_MOESM1_ESM.docx (138 kb)
Supplementary material 1 (DOCX 137 kb)

References

  1. 1.
    Pondé NF, Zardavas D, Piccart M (2019) Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 16:27–44.  https://doi.org/10.1038/s41571-018-0089-9 CrossRefPubMedGoogle Scholar
  2. 2.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672.  https://doi.org/10.1056/NEJMoa052306 CrossRefGoogle Scholar
  3. 3.
    Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744–3752.  https://doi.org/10.1200/JCO.2014.55.5730 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 32:2159–2165.  https://doi.org/10.1200/JCO.2013.53.9288 CrossRefPubMedGoogle Scholar
  5. 5.
    Advani PP, Ballman KV, Dockter TJ et al (2016) Long-term cardiac safety analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 34:581–587.  https://doi.org/10.1200/JCO.2015.61.8413 CrossRefPubMedGoogle Scholar
  6. 6.
    Romond EH, Jeong J-H, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792–3799.  https://doi.org/10.1200/JCO.2011.40.0010 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pondé NF, Lambertini M, de Azambuja E (2016) Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 1:e000073.  https://doi.org/10.1136/esmoopen-2016-000073 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684.  https://doi.org/10.1056/NEJMoa052122 CrossRefGoogle Scholar
  9. 9.
    Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382:1021–1028.  https://doi.org/10.1016/S0140-6736(13)61094-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Hervent A-S, De Keulenaer GW (2012) Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci 13:12268–12286.  https://doi.org/10.3390/ijms131012268 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Crone SA, Zhao Y-Y, Fan L et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465.  https://doi.org/10.1038/nm0502-459 CrossRefPubMedGoogle Scholar
  12. 12.
    Grazette LP, Boecker W, Matsui T et al (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44:2231–2238.  https://doi.org/10.1016/j.jacc.2004.08.066 CrossRefPubMedGoogle Scholar
  13. 13.
    ElZarrad MK, Mukhopadhyay P, Mohan N et al (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS ONE 8:e79543.  https://doi.org/10.1371/journal.pone.0079543 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2902.  https://doi.org/10.1200/JCO.2005.05.827 CrossRefPubMedGoogle Scholar
  15. 15.
    Ewer MS, Ewer SM (2015) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12:547–558.  https://doi.org/10.1038/nrcardio.2015.65 CrossRefPubMedGoogle Scholar
  16. 16.
    Zardavas D, Suter TM, Van Veldhuisen DJ et al (2017) Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage Human Epidermal Growth Factor Receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35:878–884.  https://doi.org/10.1200/JCO.2015.65.7916 CrossRefPubMedGoogle Scholar
  17. 17.
    Ponde N, Bradbury I, Lambertini M et al (2018) Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 168:631–638.  https://doi.org/10.1007/s10549-017-4628-3 CrossRefPubMedGoogle Scholar
  18. 18.
    Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al (2017) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19:9–42.  https://doi.org/10.1002/ejhf.654 CrossRefPubMedGoogle Scholar
  19. 19.
    Earl HM, Hiller L, Vallier A-L et al (2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet.  https://doi.org/10.1016/S0140-6736(19)30650-6 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pivot X, Romieu G, Debled M et al (2019) 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 393:2591–2598.  https://doi.org/10.1016/S0140-6736(19)30653-1 CrossRefPubMedGoogle Scholar
  21. 21.
    von Minckwitz G, Procter M, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131.  https://doi.org/10.1056/NEJMoa1703643 CrossRefGoogle Scholar
  22. 22.
    Henry ML, Niu J, Zhang N et al (2018) Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 11:1084–1093.  https://doi.org/10.1016/j.jcmg.2018.06.005 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283.  https://doi.org/10.1056/NEJMoa0910383 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tolaney SM, Guo H, Pernas S et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 37:1868–1875.  https://doi.org/10.1200/JCO.19.00066 CrossRefPubMedGoogle Scholar
  25. 25.
    Gulati G, Heck SL, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671–1680.  https://doi.org/10.1093/eurheartj/ehw022 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Pituskin E, Mackey JR, Koshman S et al (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101–Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870–877.  https://doi.org/10.1200/JCO.2016.68.7830 CrossRefGoogle Scholar
  27. 27.
    Guglin M, Krischer J, Tamura R et al (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73:2859–2868.  https://doi.org/10.1016/j.jacc.2019.03.495 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Evandro de Azambuja
    • 1
    Email author
  • Noam Ponde
    • 1
    • 2
  • Marion Procter
    • 3
  • Priya Rastogi
    • 4
  • Reena S. Cecchini
    • 5
  • Matteo Lambertini
    • 1
    • 6
  • Karla Ballman
    • 5
  • Alvaro Moreno Aspitia
    • 7
  • Dimitrios Zardavas
    • 8
  • Lise Roca
    • 9
  • Richard D. Gelber
    • 10
  • Martine Piccart-Gebhart
    • 1
    • 8
  • Thomas Suter
    • 11
  1. 1.Institut Jules Bordet, Université Libre de Bruxelles (U.L.B)BrusselsBelgium
  2. 2.AC Camargo Cancer CenterSao PauloBrazil
  3. 3.Frontier Science (Scotland)KincraigUK
  4. 4.NRG Oncology, and The University of Pittsburgh Medical CenterPittsburghUSA
  5. 5.NRG Oncology, and the University of PittsburghPittsburghUSA
  6. 6.IRCCS Ospedale Policlinico San Martino and University of GenovaGENOVAItaly
  7. 7.Mayo ClinicJacksonvilleUSA
  8. 8.Breast International Group (BIG)BrusselsBelgium
  9. 9.Institut Regional du Cancer Montpellier Val d’AurelleMontpellierFrance
  10. 10.Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science and Technology Research FoundationBostonUSA
  11. 11.University Hospital BernBernSwitzerland

Personalised recommendations